Remember
 
 
At SpeculatingStocks You Can Discover Stocks, Post Anonymously, and React to Posts. Login is Optional.
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Biotech Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Biotech Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: biotech, biotechnology, biopharma, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Biotech.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to biotech; however, a few may just somewhat depend and/or be indirectly related to biotech. As always complete your own due diligence.


Biotech Stocks & ETFs


Symbol
Company / ETF Name
Market Cap

774.25M429.89M12.47M66.57M38.85M3.42B52.96M11.55M1.52B7.36B1.82B99.87B30.04B282.61M144.05M469.34M17.36M18.57M154.89M122.07B258.03M491.23M7.91B38.66M7.57M26.77M1.01B608.47M29.95M46.41M11.67M98.55M272.84M49.06B75.22M235.91M8






69.73M754.33M722.52M2.17B324.9M309.01M27.64M145.06MN/AN/A126.79M1.9B72.51M839.26M2.65B360.11B84.49B43.94M6.01B3.08B319.52M54.64M654.6M23.83M4.42B3.79B9.13M391.15M341.28M204.98M218.04M3.59M297.73M661.43M8.74B50.55M16.74M39.86M57.21M449.86M2.77B1.93B34.34M780.65M2.52M8.68B22.86M13.41M479.47MN/AN/A42.12M144.14M84.93B136.14M486.46M8.13M107.91M247.52k321.75M16.35M2.22M2.61B67.4M4.71M363.36M17.55M598.14M667.21M25.04B21.7M3.91M924.63M34.98B114.14B15.36B16.11B193.81B31.77B111.17B30.83M115.1M304.84MN/A97.4M

08/17/2017: Here are 4 top biotech stock ideas from JPMorgan



08/16/2017: Goldman has a new favorite biotech because of potential Alzheimer's blockbuster



08/07/2017: Here are 4 top biotech stock ideas from Jefferies



08/01/2017: Jurors ask about fraud 'intent' at Martin Shkreli trial; 'pharma bro' reads Warren Buffett biography



07/27/2017: Martin Shkreli's lawyer says former drug company chairman tried to 'seduce' the 'pharma bro'



07/26/2017: Three biotech companies to watch ahead of earnings



07/25/2017: Three biotech companies to watch ahead of earnings



07/24/2017: Bipartisan political squabbling over drug prices has already cost biotech companies $21 billion



07/18/2017: Vertex Pharma shares surge 26%; 3-drug combo aids breathing in some cystic fibrosis patients



07/18/2017: Vertex Pharma's three-drug combinations improve breathing in some cystic fibrosis patients



07/18/2017: TipRanks: Here are the 5 favorite biotech stocks of top analysts



07/14/2017: Here is Credit Suisse's strategy on biotechnology stocks into earnings



07/13/2017: Sale process for biotech Tesaro seen unlikely to result in deal



07/06/2017: Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'



07/06/2017: Alexion Pharmaceuticals reportedly under investigation by HHS



07/05/2017: Shkreli prosecutors reveal plea deal request by 'pharma bro' lawyer as judge tells Shkreli to shut up



07/04/2017: Shkreli's lawyer objects to gag order, blames media for baiting 'pharma bro'



07/03/2017: Prosecutors seek gag order for pharma bro Martin Shkreli after his courthouse rant



07/03/2017: Prosecutors seek gag order for pharma bro Martin Shkreli after his courthouse rant against them




Recent Biotech Posts (Pulses)




08/18/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 27.63%. -- Go to this Pulse Post



08/18/2017: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 32.77%. -- Go to this Pulse Post



08/18/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 54.64%. -- Go to this Pulse Post



08/17/2017: $ABUS (Arbutus Biopharma Corporation) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(5.65M). -- Go to this Pulse Post



08/17/2017: $ABUS (Arbutus Biopharma Corporation) did not produce a profit last quarter with Quarterly Net Income of $(18.26M). -- Go to this Pulse Post



08/16/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(7.81M). -- Go to this Pulse Post



08/16/2017: $NAVB (Navidea Biopharmaceuticals, Inc) did not produce a profit last quarter with Quarterly Net Income of $(3.15M). -- Go to this Pulse Post



08/15/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.5. -- Go to this Pulse Post



08/15/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 12.37%. -- Go to this Pulse Post



08/15/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.30%. -- Go to this Pulse Post



08/12/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 24.25%. -- Go to this Pulse Post



08/12/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 54.69%. -- Go to this Pulse Post



08/12/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 24.62%. -- Go to this Pulse Post



08/12/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 78.20%. -- Go to this Pulse Post



08/11/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.46. -- Go to this Pulse Post



08/11/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 12.22%. -- Go to this Pulse Post



08/11/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.38%. -- Go to this Pulse Post



08/11/2017: $ABUS (Arbutus Biopharma Corporation) has significant institutional ownership of at least 20% with institutional ownership of 68.57%. -- Go to this Pulse Post



08/11/2017: $KERX (Keryx Biopharmaceuticals Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $49.62M. -- Go to this Pulse Post



08/11/2017: $KERX (Keryx Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(86.5M). -- Go to this Pulse Post



08/11/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 24.17%. -- Go to this Pulse Post



08/11/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 54.91%. -- Go to this Pulse Post



08/11/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 28.00%. -- Go to this Pulse Post



08/11/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 78.08%. -- Go to this Pulse Post



08/10/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.86. -- Go to this Pulse Post



08/10/2017: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.91. -- Go to this Pulse Post



08/10/2017: $ABIO (ARCA biopharma, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $2.93M. -- Go to this Pulse Post



08/10/2017: $ABIO (ARCA biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(5.52M). -- Go to this Pulse Post



08/10/2017: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 32.80%. -- Go to this Pulse Post



08/10/2017: $ABIO (ARCA biopharma, Inc.) is a low float stock with only 4.82M shares in its float. -- Go to this Pulse Post



07/31/2017: Three companies recently holding their Initial Public Offering: $NEWA (Newater Technolo), $RDFN (Redfin Corp), $SNNA (Sienna Biopharma). -- Go to this Pulse Post



07/31/2017: $RDHL RedHill Biopharma received unanimous positive recommendation from DSMB to continue Phase III study with RHB-104 for Crohn's disease as planned. -- Go to this Pulse Post



07/31/2017: $IPCI Intellipharmaceutics Intl to 'vigorously defend against the allegations set forth' in the US District Court for the Southern District of New York. -- Go to this Pulse Post



07/30/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 28.43%. -- Go to this Pulse Post



07/29/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 118.75. -- Go to this Pulse Post



07/29/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 54.28%. -- Go to this Pulse Post



07/29/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 24.17%. -- Go to this Pulse Post



07/28/2017: Three companies recently holding their Initial Public Offering: $INDUU (Industrea Acquis), $WRLSU (Pensare Acquisit), $SNNA (Sienna Biopharma). -- Go to this Pulse Post



07/27/2017: $DPLO Diplomat Pharmacy has been selected to provide specialty pharmacy services for Labor Value Rx's Pipe Trade Services of MN (:PTSMN) members. -- Go to this Pulse Post



07/27/2017: $SNNA Sienna Biopharmaceuticals opens for trading at $19.05 after pricing IPO at $15.00. -- Go to this Pulse Post



07/27/2017: $ABUS Arbutus Biopharma received notice of termination from Alexion for the companies' LNP license agreement. -- Go to this Pulse Post



07/27/2017: $KERX Keryx Biopharma missed by $0.60, beat on revenue; raised US Auryxia sales guidance. -- Go to this Pulse Post



07/27/2017: $SNNA Sienna Biopharmaceuticals (Nasdqaq) priced 4.333M share IPO at $15.00 per share, at the mid-pt of the $14-16 expected range. -- Go to this Pulse Post



07/27/2017: $IPCI Intellipharmaceutics Intl provided update on FDA Advisory Committees Meeting for Rexista. -- Go to this Pulse Post



07/26/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.00%. -- Go to this Pulse Post



07/25/2017: $AXSM Axsome Therapeutics reported positive topline clinical trial results from a Phase 1 pharmacokinetic study of AXS-06, a novel, oral, non-opioid, fixed-dose combination of meloxicam and esomeprazole being developed for the treatment of osteoarthritis and rheumatoid arthritis. -- Go to this Pulse Post



07/25/2017: $RDHL RedHill Biopharma beat Q2 estimates. -- Go to this Pulse Post



07/25/2017: $PCRX Pacira Pharma completed two Phase 3 placebo-controlled studies evaluating the efficacy, safety and pharmacokinetics of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose nerve block for prolonged regional analgesia. -- Go to this Pulse Post



07/24/2017: $HEB (Hemispherx Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 29.17. -- Go to this Pulse Post



07/24/2017: $AMAG AMAG Pharma launched Intrarosa (prasterone) at pharmacies nationwide to treat moderate to severe dyspareunia due to menopause. -- Go to this Pulse Post



07/23/2017: $ABIO (ARCA biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(1.23M). -- Go to this Pulse Post



07/23/2017: $ABIO (ARCA biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(4.34M). -- Go to this Pulse Post



07/21/2017: $NEXS (Nexus Biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(225). -- Go to this Pulse Post



07/21/2017: $NEXS (Nexus Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(109,188). -- Go to this Pulse Post



07/21/2017: $TBPH (Theravance Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 80.68%. -- Go to this Pulse Post



07/21/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 67.66. -- Go to this Pulse Post



07/21/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 37.51. -- Go to this Pulse Post



07/21/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 28.44%. -- Go to this Pulse Post



07/21/2017: $RDHL (RedHill Biopharma Ltd.) could become a potential short squeeze opportunity with significant short interest of 12.70. -- Go to this Pulse Post



07/19/2017: $TBPH Theravance Biopharma and Mylan announce positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (:LAMA) and a proposed once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive... -- Go to this Pulse Post



07/19/2017: $TBPH (Theravance Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 80.76%. -- Go to this Pulse Post



07/19/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 36.66%. -- Go to this Pulse Post



07/19/2017: $TBPH (Theravance Biopharma, Inc.) is a low float stock with only 3.18M shares in its float. -- Go to this Pulse Post



07/18/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 59.58%. -- Go to this Pulse Post



07/18/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 27.43%. -- Go to this Pulse Post



07/18/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 25.08%. -- Go to this Pulse Post



07/18/2017: $ARRY Array Biopharma and Amgen announce collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. -- Go to this Pulse Post



07/17/2017: $RDHL RedHill Biopharma has enrolled last patient in the Phase II study with BEKINDA (RHB-102)1 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome. -- Go to this Pulse Post



07/16/2017: $RDHL (RedHill Biopharma Ltd.) has significant insider ownership of at least 20% with insider ownership of 24.43%. -- Go to this Pulse Post



07/15/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 59.60%. -- Go to this Pulse Post



07/15/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 23.05%. -- Go to this Pulse Post



07/15/2017: $RDHL (RedHill Biopharma Ltd.) has significant insider ownership of at least 20% with insider ownership of 24.63%. -- Go to this Pulse Post



07/15/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 98.05%. -- Go to this Pulse Post



07/15/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.35%. -- Go to this Pulse Post



07/14/2017: $SBBP (Strongbridge Biopharma plc) has significant insider ownership of at least 20% with insider ownership of 71.12%. -- Go to this Pulse Post



07/13/2017: $ABIO (ARCA biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 41.69%. -- Go to this Pulse Post



07/12/2017: $RDHL RedHill Biopharma released timeline for DSMB meetings and update on RHB-104 enrollment. -- Go to this Pulse Post



07/12/2017: $CARA Cara Therapeutics announced summary results from its Phase 1 safety and pharmacokinetic trial of Oral CR845 in chronic kidney disease patients undergoing hemodialysis. -- Go to this Pulse Post



07/12/2017: $MSDI Monster Digital merger partner Innovate Biopharma submitted an app to the FDA seeking orphan drug designation for INN-108 as an oral therapy proposed for the treatment of pediatric ulcerative colitis. -- Go to this Pulse Post



07/12/2017: $GALE Galena Biopharma provided an update on the Phase 2b trial in node positive and triple negative HER2 IHC 1+/2+ patients in combination with trastuzumab; study is nearly fully enrolled with 293 of the 300 patients enrolled to date; continues to evaluate strategic opportunities. -- Go to this Pulse Post



07/10/2017: $RNN Rexahn Pharmaceuticals received NOA from the USPTO covering indications, dosage regimens and pharmacokinetic profile for RX-3117, expected to provide protection to 2036. -- Go to this Pulse Post



07/10/2017: $HEB Hemispherx Biopharma announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen immuno-oncology therapy in an Early Access Program managed by myTomorrows. -- Go to this Pulse Post



07/09/2017: $HEB (Hemispherx Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 26.59. -- Go to this Pulse Post



07/09/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 28.51%. -- Go to this Pulse Post



07/09/2017: $TBPH (Theravance Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 80.92%. -- Go to this Pulse Post



07/08/2017: $ABIO (ARCA biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(694,000). -- Go to this Pulse Post



07/08/2017: $ABIO (ARCA biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(4.24M). -- Go to this Pulse Post



07/08/2017: $ABUS (Arbutus Biopharma Corporation) has significant insider ownership of at least 20% with insider ownership of 68.57%. -- Go to this Pulse Post



07/07/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 29.45%. -- Go to this Pulse Post



07/05/2017: $RDHL (RedHill Biopharma Ltd.) has significant insider ownership of at least 20% with insider ownership of 24.62%. -- Go to this Pulse Post



07/05/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 59.33%. -- Go to this Pulse Post



07/05/2017: $ABIO (ARCA biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 41.68%. -- Go to this Pulse Post



07/05/2017: $ARRY Array Biopharma announced the submission of two New NDAs to the FDA to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. -- Go to this Pulse Post



07/04/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 28.51%. -- Go to this Pulse Post



07/04/2017: $TBPH (Theravance Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 81.07%. -- Go to this Pulse Post



07/04/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 42.91%. -- Go to this Pulse Post



07/04/2017: $KYTH (Kythera Biopharmaceuticals, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $716,677. -- Go to this Pulse Post



07/04/2017: $KYTH (Kythera Biopharmaceuticals, Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $57,633. -- Go to this Pulse Post



07/04/2017: $ABPI (Accentia Biopharmaceuticals, Inc.) could become a potential short squeeze opportunity with significant short interest of 89.76. -- Go to this Pulse Post



07/04/2017: $ABPI (Accentia Biopharmaceuticals, Inc.) is a low float stock with only 2.16M shares in its float. -- Go to this Pulse Post



07/04/2017: $MSDI Monster Digital signed merger agreement; Innovate Biopharma will become the company's majority owners --halted. -- Go to this Pulse Post



07/03/2017: $MSDI Monster Digital signed merger agreement; Innovate Biopharma will become the company's majority owners --halted. -- Go to this Pulse Post



07/01/2017: $GALE (Galena Biopharma, Inc.) has significant insider ownership of at least 20% with insider ownership of 29.60%. -- Go to this Pulse Post



07/01/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 97.99%. -- Go to this Pulse Post



07/01/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 26.97%. -- Go to this Pulse Post



07/01/2017: $ABUS (Arbutus Biopharma Corporation) has significant insider ownership of at least 20% with insider ownership of 68.56%. -- Go to this Pulse Post